Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 13 | 2023 | 151 | 4.240 |
Why?
|
| Rhinitis | 12 | 2023 | 136 | 3.670 |
Why?
|
| Paranasal Sinuses | 5 | 2022 | 61 | 1.580 |
Why?
|
| Nasal Polyps | 6 | 2023 | 51 | 1.300 |
Why?
|
| Immunosuppressive Agents | 2 | 2019 | 113 | 1.130 |
Why?
|
| Paranasal Sinus Neoplasms | 4 | 2022 | 59 | 1.100 |
Why?
|
| Endoscopy | 9 | 2023 | 166 | 0.970 |
Why?
|
| Chronic Disease | 11 | 2023 | 375 | 0.850 |
Why?
|
| Betacoronavirus | 5 | 2020 | 69 | 0.760 |
Why?
|
| Coronavirus Infections | 5 | 2020 | 79 | 0.730 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 82 | 0.720 |
Why?
|
| Skull Base Neoplasms | 1 | 2021 | 17 | 0.710 |
Why?
|
| Papilloma, Inverted | 1 | 2020 | 16 | 0.630 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 165 | 0.590 |
Why?
|
| Nasal Mucosa | 1 | 2018 | 13 | 0.570 |
Why?
|
| Humans | 34 | 2023 | 22914 | 0.570 |
Why?
|
| Retrospective Studies | 17 | 2023 | 2994 | 0.570 |
Why?
|
| Neutrophils | 1 | 2018 | 90 | 0.550 |
Why?
|
| Otolaryngology | 4 | 2021 | 24 | 0.540 |
Why?
|
| Invasive Fungal Infections | 1 | 2017 | 5 | 0.520 |
Why?
|
| Mucormycosis | 1 | 2017 | 8 | 0.520 |
Why?
|
| Aspergillosis | 1 | 2017 | 11 | 0.520 |
Why?
|
| Frozen Sections | 1 | 2017 | 14 | 0.520 |
Why?
|
| Nose Neoplasms | 3 | 2022 | 35 | 0.510 |
Why?
|
| Middle Aged | 15 | 2023 | 7896 | 0.400 |
Why?
|
| Adult | 11 | 2023 | 6913 | 0.360 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2021 | 33 | 0.340 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 26 | 0.320 |
Why?
|
| Simulation Training | 2 | 2020 | 34 | 0.310 |
Why?
|
| Male | 14 | 2021 | 12439 | 0.310 |
Why?
|
| Female | 14 | 2021 | 12936 | 0.310 |
Why?
|
| Nose | 2 | 2021 | 32 | 0.300 |
Why?
|
| Cerebrospinal Fluid Leak | 3 | 2023 | 15 | 0.270 |
Why?
|
| Internship and Residency | 2 | 2021 | 198 | 0.270 |
Why?
|
| Aged | 10 | 2023 | 7429 | 0.270 |
Why?
|
| Tertiary Care Centers | 3 | 2020 | 66 | 0.230 |
Why?
|
| Mometasone Furoate | 2 | 2022 | 7 | 0.230 |
Why?
|
| Skull Base | 2 | 2023 | 30 | 0.230 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 800 | 0.230 |
Why?
|
| Inflammation | 3 | 2023 | 231 | 0.220 |
Why?
|
| Intracranial Hypertension | 1 | 2023 | 12 | 0.200 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 1 | 2023 | 13 | 0.200 |
Why?
|
| Olfaction Disorders | 2 | 2021 | 36 | 0.200 |
Why?
|
| Treatment Outcome | 4 | 2023 | 2940 | 0.190 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 105 | 0.180 |
Why?
|
| Pandemics | 5 | 2020 | 206 | 0.180 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2021 | 49 | 0.180 |
Why?
|
| Surgical Flaps | 1 | 2021 | 50 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2021 | 82 | 0.170 |
Why?
|
| Child | 2 | 2022 | 1156 | 0.170 |
Why?
|
| Professional Role | 1 | 2021 | 28 | 0.170 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 52 | 0.170 |
Why?
|
| Melanoma | 1 | 2021 | 49 | 0.170 |
Why?
|
| Air Pollutants | 1 | 2021 | 11 | 0.170 |
Why?
|
| Air Pollution | 1 | 2021 | 14 | 0.170 |
Why?
|
| Natural Killer T-Cells | 1 | 2020 | 3 | 0.170 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2020 | 3 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2022 | 575 | 0.170 |
Why?
|
| Hemostatic Techniques | 1 | 2020 | 6 | 0.170 |
Why?
|
| Nasal Surgical Procedures | 2 | 2017 | 10 | 0.160 |
Why?
|
| Epistaxis | 1 | 2020 | 9 | 0.160 |
Why?
|
| Nasopharynx | 1 | 2020 | 5 | 0.160 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2020 | 6 | 0.160 |
Why?
|
| Personnel, Hospital | 1 | 2020 | 15 | 0.160 |
Why?
|
| Smell | 1 | 2020 | 13 | 0.160 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 295 | 0.160 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2020 | 11 | 0.160 |
Why?
|
| Airway Management | 1 | 2020 | 15 | 0.160 |
Why?
|
| Tracheostomy | 1 | 2020 | 20 | 0.160 |
Why?
|
| Urban Health Services | 1 | 2020 | 12 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 70 | 0.160 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 2020 | 7 | 0.160 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 21 | 0.160 |
Why?
|
| Surgeons | 1 | 2021 | 78 | 0.160 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 27 | 0.160 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2020 | 5 | 0.160 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 138 | 0.160 |
Why?
|
| Sella Turcica | 1 | 2019 | 3 | 0.160 |
Why?
|
| Surgical Wound | 1 | 2019 | 8 | 0.160 |
Why?
|
| Preoperative Care | 1 | 2020 | 107 | 0.160 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2019 | 28 | 0.150 |
Why?
|
| Carcinoma | 1 | 2020 | 64 | 0.150 |
Why?
|
| Disease Management | 1 | 2020 | 100 | 0.150 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2020 | 52 | 0.150 |
Why?
|
| Wound Healing | 1 | 2019 | 108 | 0.150 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 311 | 0.150 |
Why?
|
| Maxillary Diseases | 1 | 2018 | 4 | 0.150 |
Why?
|
| Phenotype | 1 | 2019 | 260 | 0.150 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 109 | 0.150 |
Why?
|
| Young Adult | 3 | 2020 | 1651 | 0.150 |
Why?
|
| Telemedicine | 1 | 2020 | 85 | 0.150 |
Why?
|
| Fibrosis | 1 | 2018 | 30 | 0.140 |
Why?
|
| Clinical Competence | 1 | 2020 | 190 | 0.140 |
Why?
|
| Olfactory Nerve | 1 | 2017 | 2 | 0.140 |
Why?
|
| Olfactory Receptor Neurons | 1 | 2017 | 2 | 0.140 |
Why?
|
| Frontal Sinus | 1 | 2017 | 13 | 0.130 |
Why?
|
| Mucor | 1 | 2017 | 5 | 0.130 |
Why?
|
| Aspergillus | 1 | 2017 | 7 | 0.130 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 3720 | 0.130 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 42 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 201 | 0.130 |
Why?
|
| Acute Disease | 1 | 2017 | 163 | 0.120 |
Why?
|
| Postoperative Complications | 1 | 2021 | 812 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 443 | 0.120 |
Why?
|
| Decision Making | 1 | 2017 | 175 | 0.110 |
Why?
|
| Prognosis | 3 | 2021 | 717 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2021 | 1496 | 0.090 |
Why?
|
| Immunotherapy | 2 | 2021 | 50 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2021 | 227 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2021 | 309 | 0.080 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 352 | 0.080 |
Why?
|
| Survival Rate | 2 | 2020 | 314 | 0.070 |
Why?
|
| Chicago | 2 | 2020 | 813 | 0.070 |
Why?
|
| Risk Factors | 2 | 2021 | 1968 | 0.060 |
Why?
|
| Adolescent | 2 | 2020 | 1877 | 0.060 |
Why?
|
| Encephalocele | 1 | 2023 | 18 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 31 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2023 | 482 | 0.050 |
Why?
|
| Eosinophils | 1 | 2022 | 36 | 0.050 |
Why?
|
| Nasal Lavage | 1 | 2021 | 3 | 0.050 |
Why?
|
| Pituitary-Adrenal System | 1 | 2021 | 9 | 0.040 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2021 | 21 | 0.040 |
Why?
|
| Tourette Syndrome | 1 | 2021 | 10 | 0.040 |
Why?
|
| Hydrocortisone | 1 | 2021 | 29 | 0.040 |
Why?
|
| Taste Disorders | 1 | 2021 | 4 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 29 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 165 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2021 | 18 | 0.040 |
Why?
|
| Particulate Matter | 1 | 2021 | 16 | 0.040 |
Why?
|
| Observer Variation | 1 | 2021 | 83 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 271 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 40 | 0.040 |
Why?
|
| Surgery Department, Hospital | 1 | 2020 | 3 | 0.040 |
Why?
|
| Logistic Models | 1 | 2021 | 351 | 0.040 |
Why?
|
| Education, Nursing, Continuing | 1 | 2020 | 9 | 0.040 |
Why?
|
| Inservice Training | 1 | 2020 | 23 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 35 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 19 | 0.040 |
Why?
|
| Nasal Cavity | 1 | 2020 | 31 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 30 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 64 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2020 | 13 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2020 | 52 | 0.040 |
Why?
|
| Emergencies | 1 | 2020 | 28 | 0.040 |
Why?
|
| Genomics | 1 | 2020 | 51 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2020 | 29 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 48 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 196 | 0.040 |
Why?
|
| Patient Selection | 1 | 2020 | 167 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 256 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 376 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 593 | 0.040 |
Why?
|
| Mass Screening | 1 | 2020 | 160 | 0.040 |
Why?
|
| Smoking | 1 | 2019 | 159 | 0.040 |
Why?
|
| Eosinophilia | 1 | 2018 | 36 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 256 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 634 | 0.030 |
Why?
|
| Time Factors | 1 | 2021 | 1263 | 0.030 |
Why?
|
| Cadaver | 1 | 2017 | 282 | 0.030 |
Why?
|
| United States | 1 | 2020 | 1763 | 0.030 |
Why?
|
Papagiannopoulos's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(160)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(13)
People in Profiles who have published with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_